MedDataX Logo

Radiofrequency-assisted Liver Resection in Intractable Liver Cancer

NCT ID: NCT04413526

Last Updated: 2021-11-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

199 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-05-25

Study Completion Date

2021-11-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this retrospective study, the investigators assessed the application of radiofrequency-assisted liver resection in intractable liver cancer resection, and plan to analysis the different factors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary clinical treatment of liver cancer is surgical resection, although many integrated applications develop rapidly, surgery is still the best way to remove the tumour lesion. Traditional ways that have curative removed tumours in three methods, which are liver resection, liver transplantation and radiofrequency ablation (RFA).

As for primary liver cancer, surgery, and RFA are both effective and safety, but for the complexity of end-stage liver cancer, surgical resection may not remove the tumours alone. Surgical resection with radiofrequency ablation therapy for intractable liver cancer is a kind of active plan. The therapy can eliminate the tumour, maximize the protection of patient liver tissue, reduce operation damage, reduce the incidence of complications, and improve patients quality of life after surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

RFA liver cancer surgical resection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

radiofrequency-assisted liver resection

radiofrequency-assisted liver resection for intractable liver cancer

radiofrequency

Intervention Type PROCEDURE

radiofrequency combined with liver resection

TACE(transcatheter arterial chemoembolization)

temporary TACE for intractable liver cancer

TACE

Intervention Type PROCEDURE

only TACE treatment

radiofrequency ablation plus TACE

radiofrequency ablation plus TACE for intractable liver cancer

TACE+radiofrequency

Intervention Type PROCEDURE

TACE followed by radiofrequency

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

radiofrequency

radiofrequency combined with liver resection

Intervention Type PROCEDURE

TACE

only TACE treatment

Intervention Type PROCEDURE

TACE+radiofrequency

TACE followed by radiofrequency

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ultrasound-guided fine-needle aspiration pathology or postoperative pathology was confirmed to be liver cancer, no pathological results according to China 's 2017 version of the hepatocarcinoma (HCC) diagnosis and treatment specifications, in line with the standard clinical diagnosis of liver cancer
* According to Barcelona Clinic Liver Cancer (BCLC) staging criteria, it is stage C (stage C: single tumour\> 5 cm or more than three tumours, and at least one tumour\> 3 cm, liver function Child-Pugh A or B, with lymph node metastasis or distant metastasis or portal vein or Venous liver trunk is invaded, penance Status (PST) score 1-2 points)

Exclusion Criteria

* HCC patients with other malignant tumours
* Metastatic liver tumour
* Patients with liver abscess
* Patients with organ dysfunction
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hepatopancreatobiliary Surgery Institute of Gansu Province

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wenbo Meng

head of surgery

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wenbo Meng, M.D., Ph. D.

Role: PRINCIPAL_INVESTIGATOR

Hepatopancreatobiliary Surgery Institute of Gansu Province

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hepatopancreatobiliary Surgery Institute of Gansu Province

Lanzhou, Gansu, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

References

Explore related publications, articles, or registry entries linked to this study.

Sun Y, Ji S, Ji H, Liu L, Li C. Clinical efficacy analysis of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in primary liver cancer and recurrent liver cancer. J BUON. 2019 Jul-Aug;24(4):1402-1407.

Reference Type BACKGROUND
PMID: 31646783 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

radiofrequency liver resection

Identifier Type: -

Identifier Source: org_study_id